| P/E (FY) | — | Sales (TTM) | $494,623 |
| Earnings (TTM) | -$11.0M | ROE | −235.50% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $5.4M | Trading Days | 3614 |
| 52W High | 6.23 |
| 52W Low | 0.28 |
| % Off High | −94.20% |
| YTD | −73.01% | 1Y | −71.75% |
| 3Y | −96.44% | 5Y | −99.85% |
| 10Y | −99.98% | Since incept. (ann.) | −43.74% |
| Ann. Volatility (1Y) | 213.45% | Ann. Volatility (3Y) | 226.48% |
| Sharpe (1Y) | 0.32 | Sharpe (3Y) | 0.20 |
| Max Drawdown (1Y) | −94.35% | Max Drawdown (3Y) | −98.20% |
| Beta (3Y, vs SPY) | 1.72 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| GOVX | GeoVax Labs, Inc. | $5.4M | — |
| LIANY | LianBio | $5.4M | — |
| APVO | Aptevo Therapeutics Inc. | $5.2M | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $5.5M | — |
| INM | InMed Pharmaceuticals Inc. | $5.5M | — |
| CURX | Curanex Pharmaceuticals Inc | $5.6M | — |
| XBIO | Xenetic Biosciences, Inc. | $5.7M | — |
| CVKD | Cadrenal Therapeutics, Inc. | $5.8M | — |
| DRMA | Dermata Therapeutics, Inc. | $5.0M | — |
| ENVB | Enveric Biosciences, Inc. | $4.9M | — |
| RNAZ | Transcode Therapeutics, Inc. |
| $4.8M |
| — |
| ACXP | Acurx Pharmaceuticals, Inc. | $6.1M | — |
